TNFRSF17 and Miyoshi myopathy: However, the cohorts of WM on active therapy (G1) and of MM on anti-CD38 and anti-BCMA regimens (G3a and G3b) were severely affected in both vaccine-induced response rates and/or magnitude resulting in their severely reduced ability to bind to Spike-RBD.